Home Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2
Article
Licensed
Unlicensed Requires Authentication

Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2

  • Ajay Kumar Shukla and Saurav Misra EMAIL logo
Published/Copyright: January 6, 2023
Journal of Basic and Clinical Physiology and Pharmacology
From the journal Journal of Basic and Clinical Physiology and Pharmacology Volume 34 Issue 2

Abstract

The COVID-19 pandemic remains a severe global threat, with the world engulfed in the struggle against the disease’s second or third waves, which are approaching frightening proportions in terms of cases and mortality in many nations. Despite the critical need for effective therapy, there is still uncertainty about the optimal practices for treating COVID-19 with various pharmaceutical approaches. This being third year, global immunity and eradication of SARS-CoV-2 is currently seems to be out of reach. Efforts to produce safe and effective vaccinations have shown promise, and progress is being made. Additional therapeutic modalities, as well as vaccine testing in children, are required for prophylaxis and treatment of high-risk individuals. As a result, neutralising antibodies and other comparable therapeutic options offer a lot of promise as immediate and direct antiviral medications. Bispecific antibodies offer a lot of potential in COVID-19 treatment because of their qualities including stability, small size and ease of manufacture. These can be used to control the virus’s infection of the lungs because they are available in an inhalational form. To combat the COVID-19 pandemic, innovative approaches with effective nanobodies, high-expression yield and acceptable costs may be required.

Keywords: bispecific antibodies; COVID-19; nanobodies
Corresponding author: Saurav Misra, MBBS, MD, Assistant professor, Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, India, Phone: +919559020384, E-mail:

  1. Research funding: None.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Yes, all authors state that there is no conflict of interest.

  4. Informed consent: Not required.

  5. Ethical approval: No requirement of ethical approval.

References

1. Wagner, TR, Schnepf, D, Beer, J, Ruetalo, N, Klingel, K, Kaiser, PD, et al.. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. EMBO Rep 2022;23:e53865. https://doi.org/10.15252/embr.202153865Search in Google Scholar PubMed PubMed Central

2. Irani, V, Guy, AJ, Andrew, D, Beeson, JG, Ramsland, PA, Richards, JS, et al.. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol 2015;67:171–82. https://doi.org/10.1016/j.molimm.2015.03.255.Search in Google Scholar PubMed

3. Köhler, G, Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7. https://doi.org/10.1038/256495a0.Search in Google Scholar PubMed

4. Jain, M, Kamal, N, Batra, SK. Engineering antibodies for clinical applications. Trends Biotechnol 2007;25:307–16. https://doi.org/10.1016/j.tibtech.2007.05.001.Search in Google Scholar PubMed

5. Kontermann, RE. Dual targeting strategies with bispecific antibodies. mAbs 2012;4:182–97. https://doi.org/10.4161/mabs.4.2.19000.Search in Google Scholar PubMed PubMed Central

6. Brinkmann, U, Kontermann, RE. The making of bispecific antibodies. mAbs 2017;9:182–212.10.1080/19420862.2016.1268307Search in Google Scholar PubMed PubMed Central

7. Scott, AM, Wolchok, JD, Old, LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278–87. https://doi.org/10.1038/nrc3236.Search in Google Scholar PubMed

8. Suurs, FV, Lub-de Hooge, MN, De Vries, EGE, De Groot, DJA. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther 2019;201:103–19. https://doi.org/10.1016/j.pharmthera.2019.04.006.Search in Google Scholar PubMed

9. Fan, G, Wang, Z, Hao, M, Li, J. Bispecific antibodies and their applications. J Hematol Oncol 2015;8:130. https://doi.org/10.1186/s13045-015-0227-0.Search in Google Scholar PubMed PubMed Central

10. Kontermann, RE, Brinkmann, U. Bispecific antibodies. Drug Discov Today 2015;20:838–47. https://doi.org/10.1016/j.drudis.2015.02.008.Search in Google Scholar PubMed

11. Spiess, C, Zhai, Q, Carter, PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015;67:95–106. https://doi.org/10.1016/j.molimm.2015.01.003.Search in Google Scholar PubMed

12. Seimetz, D, Lindhofer, H, Bokemeyer, C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010;36:458–67. https://doi.org/10.1016/j.ctrv.2010.03.001.Search in Google Scholar PubMed

13. Shatz, W, Chung, S, Li, B, Marshall, B, Tejada, M, Phung, W, et al.. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs 2013;5:872–81. https://doi.org/10.4161/mabs.26307.Search in Google Scholar PubMed PubMed Central

14. Wu, C, Ying, H, Bose, S, Miller, R, Medina, L, Santora, L, et al.. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules. mAbs 2009;1:339–47. https://doi.org/10.4161/mabs.1.4.8755.Search in Google Scholar PubMed PubMed Central

15. Tarcsa, E, Fraunhofer, W, Ghayur, T, Salfeld, J, Gu, J. Dual-variable domain immunoglobulin (DVD-IgTM) technology: a versatile, novel format for the next generation of dual-targeting biologics. In: Kontermann, RE, editor. Bispecific antibodies. Berlin, Heidelberg: Springer; 2011:171–85 pp.10.1007/978-3-642-20910-9_10Search in Google Scholar

16. Eigenbrot, C, Fuh, G. Two-in-one antibodies with dual action Fabs. Curr Opin Chem Biol 2013;17:400–5. https://doi.org/10.1016/j.cbpa.2013.04.015.Search in Google Scholar PubMed

17. Labrijn, AF, Meesters, JI, Priem, P, de Jong, RN, van den Bremer, ETJ, van Kampen, MD, et al.. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc 2014;9:2450–63. https://doi.org/10.1038/nprot.2014.169.Search in Google Scholar PubMed

18. Fischer, N, Elson, G, Magistrelli, G, Dheilly, E, Fouque, N, Laurendon, A, et al.. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun 2015;6:6113. https://doi.org/10.1038/ncomms7113.Search in Google Scholar PubMed PubMed Central

19. Le Gall, F, Kipriyanov, SM, Moldenhauer, G, LittleDi, M. Tri and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 1999;453:164–8. https://doi.org/10.1016/s0014-5793(99)00713-9.Search in Google Scholar PubMed

20. Chames, P, Baty, D. Bispecific antibodies for cancer therapy. mAbs 2009;1:539–47. https://doi.org/10.4161/mabs.1.6.10015.Search in Google Scholar PubMed PubMed Central

21. Moore, PA, Zhang, W, Rainey, GJ, Burke, S, Li, H, Huang, L, et al.. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011;117:4542–51. https://doi.org/10.1182/blood-2010-09-306449.Search in Google Scholar PubMed

22. Garber, K. Bispecific antibodies rise again. Nat Rev Drug Discov 2014;13:799–801. https://doi.org/10.1038/nrd4478.Search in Google Scholar PubMed

23. Revets, H, Baetselier, PD, Muyldermans, S. Nanobodies as novel agents for cancer therapy. Expet Opin Biol Ther 2005;5:111–24. https://doi.org/10.1517/14712598.5.1.111.Search in Google Scholar PubMed

24. Conrath, KE, Lauwereys, M, Wyns, L, Muyldermans, S. Camel single-domain antibodies as modular building units in Bispecific and bivalent antibody constructs. J Biol Chem 2001;276:7346–50. https://doi.org/10.1074/jbc.m007734200.Search in Google Scholar

25. Abraham, J. Passive antibody therapy in COVID-19. Nat Rev Immunol 2020;20:401–3. https://doi.org/10.1038/s41577-020-0365-7.Search in Google Scholar PubMed PubMed Central

26. Iwasaki, A, Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020;20:339–41. https://doi.org/10.1038/s41577-020-0321-6.Search in Google Scholar PubMed PubMed Central

27. Shukla, AK, Misra, S. Antibody-dependent enhancement of virus infection and disease: implications in COVID-19. J Basic Clin Physiol Pharmacol 2022;33:13–6. https://doi.org/10.1515/jbcpp-2021-0264.Search in Google Scholar PubMed

28. Ingram, JR, Schmidt, FI, Ploegh, HL. Exploiting nanobodies’ singular traits. Annu Rev Immunol 2018;36:695–715. https://doi.org/10.1146/annurev-immunol-042617-053327.Search in Google Scholar PubMed

29. Beirnaert, E, Desmyter, A, Spinelli, S, Lauwereys, M, Aarden, L, Dreier, T, et al.. Bivalent llama single-domain antibody fragments against tumor necrosis factor have picomolar potencies due to intramolecular interactions. Front Immunol 2017;8:867. https://doi.org/10.3389/fimmu.2017.00867.Search in Google Scholar PubMed PubMed Central

30. Koenig, PA, Das, H, Liu, H, Kümmerer, BM, Gohr, FN, Jenster, LM, et al.. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science 2021;371:eabe6230.10.1126/science.abe6230Search in Google Scholar PubMed PubMed Central

31. Sasisekharan, R. Preparing for the future - nanobodies for Covid-19? N Engl J Med 2021;384:1568–71. https://doi.org/10.1056/nejmcibr2101205.Search in Google Scholar

32. Schoof, M, Faust, B, Saunders, RA, Sangwan, S, Rezelj, V, Hoppe, N, et al.. An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking spike into an inactive conformation. BioRxiv [Preprint] 2020. https://doi.org/10.1101/2020.08.08.238469.Search in Google Scholar PubMed PubMed Central

33. Esparza, TJ, Martin, NP, Anderson, GP, Goldman, ER, Brody, DL. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci Rep 2020;10:22370. https://doi.org/10.1038/s41598-020-79036-0.Search in Google Scholar PubMed PubMed Central

34. Huo, J, Le Bas, A, Ruza, RR, Duyvesteyn, HME, Mikolajek, H, Malinauskas, T, et al.. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol 2020;27:846–54. https://doi.org/10.1038/s41594-020-0469-6.Search in Google Scholar PubMed

35. Hanke, L, Vidakovics Perez, L, Sheward, DJ, Das, H, Schulte, T, Moliner-Morro, A, et al.. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun 2020;11:4420. https://doi.org/10.1038/s41467-020-18174-5.Search in Google Scholar PubMed PubMed Central

36. Stefan, MA, Light, YK, Schwedler, JL, McIlroy, PR, Courtney, CM, Saada, EA, et al.. Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. mAbs 2021;13:1958663. https://doi.org/10.1080/19420862.2021.1958663.Search in Google Scholar PubMed PubMed Central

37. Ma, H, Zeng, W, Meng, X, Huang, X, Yang, Y, Zhao, D, et al.. Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain. J Virol 2021;95:e02438–20. https://doi.org/10.1128/jvi.02438-20.Search in Google Scholar

38. Pymm, P, Adair, A, Chan, LJ, Cooney, JP, Mordant, FL, Allison, CC, et al.. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A 2021;118:e2101918118. https://doi.org/10.1073/pnas.2101918118.Search in Google Scholar PubMed PubMed Central

39. Satta, A, Mezzanzanica, D, Turatti, F, Canevari, S, Figini, M. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol 2013;9:527–39. https://doi.org/10.2217/fon.12.203.Search in Google Scholar PubMed

40. Weidle, UH, Kontermann, RE, Brinkmann, U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol 2014;41:653–60. https://doi.org/10.1053/j.seminoncol.2014.08.004.Search in Google Scholar PubMed

41. Mullard, A. FDA approves first bispecific. Nat Rev Drug Discov 2014;14:7. https://doi.org/10.1038/nrd4531.Search in Google Scholar

42. Stanimirovic, D, Kemmerich, K, Haqqani, AS, Farrington, GK. Engineering and pharmacology of blood–brain barrier-permeable bispecific antibodies. Adv Pharmacol 2014;71:301–35.10.1016/bs.apha.2014.06.005Search in Google Scholar PubMed

43. Couch, JA, Yu, YJ, Zhang, Y, Tarrant, JM, Fuji, RN, Meilandt, WJ, et al.. Addressing safety liabilities of TfR bispecific antibodies that cross the blood– brain barrier. Sci Transl Med 2013;5:183ra57. https://doi.org/10.1126/scitranslmed.3005338.Search in Google Scholar PubMed

44. Atwal, JK, Chen, Y, Chiu, C, Mortensen, DL, Meilandt, WJ, Liu, Y, et al.. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 2011;3:84ra43. https://doi.org/10.1126/scitranslmed.3002254.Search in Google Scholar PubMed

45. Byrne, HPJC. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013;31:11. https://doi.org/10.1016/j.tibtech.2013.08.007.Search in Google Scholar PubMed PubMed Central

46. Milstein, C, Cuello, AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983;305:537–40. https://doi.org/10.1038/305537a0.Search in Google Scholar PubMed

47. Suresh, MR, Cuello, AC, Milstein, C. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc Natl Acad Sci USA 1986;83:7989–93. https://doi.org/10.1073/pnas.83.20.7989.Search in Google Scholar PubMed PubMed Central

48. Di Giandomenico, A, Keller, AE, Gao, C, Rainey, GJ, Warrener, P, Camara, MM, et al.. A multifunctional bispecific antibody protects against pseudomonas aeruginosa. Sci Transl Med 2014;6:262ra155. https://doi.org/10.1126/scitranslmed.3009655.Search in Google Scholar PubMed

49. Berg, J, Lötscher, E, Steimer, KS, Capon, DJ, Baenziger, J, Jäck, HM, et al.. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc Natl Acad Sci USA 1991;88:4723–7. https://doi.org/10.1073/pnas.88.11.4723.Search in Google Scholar PubMed PubMed Central

50. Park, SS, Ryu, CJ, Kang, YJ, Kashmiri, SVS, Hong, HJ. Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens. Mol Immunol 2000;37:1123–30. https://doi.org/10.1016/s0161-5890(01)00027-x.Search in Google Scholar PubMed

51. Taylor, RP, Martin, EN, Reinagel, ML, Nardin, A, Craig, M, Choice, Q, et al.. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol 1997;159:4035–44.10.4049/jimmunol.159.8.4035Search in Google Scholar

52. US-FDA [Home page in Internet]. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer; 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer [Accessed 24 Sep 2022].Search in Google Scholar

53. Wu, J, Fu, J, Zhang, M, Liu, D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol 2015;8:104. https://doi.org/10.1186/s13045-015-0195-4.Search in Google Scholar PubMed PubMed Central

54. Scott, LJ, Kim, ES. Emicizumab-kxwh: first global approval. Drugs 2018;78:269–74. https://doi.org/10.1007/s40265-018-0861-2.Search in Google Scholar PubMed

55. Yuan, M, Chen, X, Zhu, Y, Dong, X, Liu, Y, Qian, Z, et al.. A bispecific antibody targeting RBD and S2 potently neutralizes SARS-CoV-2 Omicron and other variants of concern. J Virol 2022;96:1–15. https://doi.org/10.1128/jvi.00775-22.Search in Google Scholar PubMed PubMed Central

56. Raghu, G, Richeldi, L, Crestani, B, Wung, P, Bejuit, R, Esperet, C, et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). Eur Respir J 2018;52:1801130. https://doi.org/10.1183/13993003.01130-2018.Search in Google Scholar PubMed

57. Creative biolabs [Home page in the Internet]. Bispecific antibody applications; 2022. Available from: https://www.creative-biolabs.com/bsab/application.htm [Accessed 24 Sep 2022].Search in Google Scholar

58. Fan, G, Wang, Z, Hao, M, Li, J. Bispecific antibodies and their applications. J Hematol Oncol 2015;8:130. https://doi.org/10.1186/s13045-015-0227-0.Search in Google Scholar PubMed PubMed Central

59. Haense, N, Atmaca, A, Pauligk, C, Steinmetz, K, Marmé, F, Haag, GM, et al.. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 2016;16:420. https://doi.org/10.1186/s12885-016-2449-0.Search in Google Scholar PubMed PubMed Central

60. Silacci, M, Lembke, W, Woods, R, Attinger-Toller, I, Baenziger-Tobler, N, Batey, S, et al.. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. mAbs 2016;8:141–9. https://doi.org/10.1080/19420862.2015.1093266.Search in Google Scholar PubMed PubMed Central

61. Ali, SO, Yu, XQ, Robbie, GJ, Wu, Y, Shoemaker, K, Yu, L, et al.. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect 2019;25:629.e1–6. https://doi.org/10.1016/j.cmi.2018.08.004.Search in Google Scholar PubMed

62. Ma, J, Mo, Y, Tang, M, Shen, J, Qi, Y, Zhao, W, et al. Bispecific antibodies: from research to clinical application. Front Immunol 2021;12:626616. https://doi.org/10.3389/fimmu.2021.626616.Search in Google Scholar PubMed PubMed Central

63. Sedykh, SE, Prinz, VV, Buneva, VN, Nevinsky, GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Dev Ther 2018;12:195–208. https://doi.org/10.2147/dddt.s151282.Search in Google Scholar
Received: 2022-03-08
Accepted: 2022-12-19
Published Online: 2023-01-06

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. The clinical potential of flavonoids in Peyronie’s disease
  4. Reviews
  5. Emphasizing roles of BDNF promoters and inducers in Alzheimer's disease for improving impaired cognition and memory
  6. Diabetic wound healing approaches: an update
  7. Metformin: new applications for an old drug
  8. Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2
  9. A review on pulmonary and mediastinal synovial sarcoma
  10. Original Articles
  11. Cytokine release by human bone marrow stromal cells isolated from osteoarthritic and diabetic osteoarthritic patients in vitro
  12. Antioxidant and anti-inflammatory effect of olive leaf extract treatment in diabetic rat brain
  13. Implication of nitrergic system in the anticonvulsant effects of ferulic acid in pentylenetetrazole-induced seizures in male mice
  14. The effects of G protein-coupled receptor 30 (GPR30) on cardiac glucose metabolism in diabetic ovariectomized female rats
  15. Effects of weight-bearing vs. non-weight-bearing endurance exercise on reducing body fat and inflammatory markers in obese females
  16. [Lys5,MeLeu9,Nle10]-NKA(4–10) induces neurokinin 2 receptor mediated urination and defecation and neurokinin 1 receptor mediated flushing in rats: measured using the rapid detection voiding assay
  17. Single 30 min treadmill exercise session suppresses the production of pro-inflammatory cytokines and oxidative stress in obese female adolescents
  18. Letter to the Editor
  19. Effect of tirzepatide on prediabetics and blood pressure with implications for future research
https://doi.org/10.1515/jbcpp-2022-0068
Keywords for this article
bispecific antibodies; COVID-19; nanobodies

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. The clinical potential of flavonoids in Peyronie’s disease
  4. Reviews
  5. Emphasizing roles of BDNF promoters and inducers in Alzheimer's disease for improving impaired cognition and memory
  6. Diabetic wound healing approaches: an update
  7. Metformin: new applications for an old drug
  8. Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2
  9. A review on pulmonary and mediastinal synovial sarcoma
  10. Original Articles
  11. Cytokine release by human bone marrow stromal cells isolated from osteoarthritic and diabetic osteoarthritic patients in vitro
  12. Antioxidant and anti-inflammatory effect of olive leaf extract treatment in diabetic rat brain
  13. Implication of nitrergic system in the anticonvulsant effects of ferulic acid in pentylenetetrazole-induced seizures in male mice
  14. The effects of G protein-coupled receptor 30 (GPR30) on cardiac glucose metabolism in diabetic ovariectomized female rats
  15. Effects of weight-bearing vs. non-weight-bearing endurance exercise on reducing body fat and inflammatory markers in obese females
  16. [Lys5,MeLeu9,Nle10]-NKA(4–10) induces neurokinin 2 receptor mediated urination and defecation and neurokinin 1 receptor mediated flushing in rats: measured using the rapid detection voiding assay
  17. Single 30 min treadmill exercise session suppresses the production of pro-inflammatory cytokines and oxidative stress in obese female adolescents
  18. Letter to the Editor
  19. Effect of tirzepatide on prediabetics and blood pressure with implications for future research
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 24.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2022-0068/html?lang=en
Scroll to top button